Whatever Happened To Industry's Interest In Ebola?

The story of the year for the biopharmaceutical industry in 2015 was most certainly the rumpus over drug prices – whether it was the uproar over the jacked up costs of older products by Turing Pharmaceuticals AG and Valeant Pharmaceuticals International Inc. or the deals the new kids on the block, the proprotein convertase subtilisin/kexin 9 inhibitors, Sanofi SA's and Regeneron Pharmaceuticals Inc.'s Praluent (alirocumab) and Amgen Inc.'s Repatha (evolocumab), had to make with payers to get past the fray.